Literature DB >> 15660966

CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.

Rosemary Jose1, Adithan Chandrasekaran, Soya Sisy Sam, Nathalie Gerard, Shashindran Chanolean, Benny K Abraham, K Satyanarayanamoorthy, Anitha Peter, Krishnamoorthy Rajagopal.   

Abstract

The aim of the study was to establish the frequencies of CYP2C9*1, *2, *3 and CYP2C19*1, *2 and *3 in the south Indian population and to compare them with the inter-racial distribution of the CYP2C9 and CYP2C19 genetic polymorphisms. Genotyping analyses of CYP2C9 and CYP2C19 were conducted in unrelated, healthy volunteers from the three south Indian states of Andhra Pradesh, Karnataka and Kerala, by the polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP). The allele frequencies of the populations of these three states were then pooled with our previous genotyping data of Tamilians (also in south India), to arrive at the distribution of CYP2C9 and CYP2C19 alleles in the south Indian population. Frequencies of CYP2C9 and CYP2C19 alleles and genotypes among various populations were compared using the two-tailed Fisher's exact test. The frequencies of CYP2C9*1, *2 and *3 in the south Indian population were 0.88 (95% CI 0.85-0.91), 0.04 (95% CI 0.02-0.06) and 0.08 (95% CI 0.06-0.11), respectively. The frequencies of CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3 were 0.78 (95% CI 0.74-0.82), 0.05 (95% CI 0.03-0.07), 0.15 (95% CI 0.12-0.18), 0.01 (95% CI 0.0-0.02), 0.01 (95% CI 0.0-0.02) and 0.0, respectively. CYP2C19*1, *2 and *3 frequencies were 0.64 (95% CI 0.60-0.68), 0.35 (95% CI 0.31-0.39) and 0.01 (95% CI 0.0-0.03), respectively. As a result of a significant heterogeneity, the data on CYP2C19 genotype frequencies were not pooled. The frequency of CYP2C9*2 mutant alleles in south Indians was higher than in Chinese and Caucasians, while CYP2C9*3 was similar to Caucasians. CYP2C19*2 was higher than in other major populations reported so far. The relatively high CYP2C19 poor-metabolizer genotype frequency of 12.6% indicates that over 28 million south Indians are poor metabolizers of CYP2C19 substrates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660966     DOI: 10.1111/j.1472-8206.2004.00307.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  33 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

3.  Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.

Authors:  Faiza Yasmeen; Muhammad Bilal Ghafoor; Abdul Wadood Khalid; Waqas Latif; Shahida Mohsin; Shagufta Khaliq
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

4.  Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Authors:  Dhakchinamoorthi Krishna Kumar; Deepak Gopal Shewade; Marie-Anne Loriot; Philippe Beaune; Jayaraman Balachander; B V Sai Chandran; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2013-09-10       Impact factor: 2.953

Review 5.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

7.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

8.  Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

Authors:  Robabeh Ghiyas Tabari; Abdoljalal Marjani; Ogholdondy Agh Ataby; Azad Reza Mansourian; Nader Mansour Samai
Journal:  Oman Med J       Date:  2013-07

9.  Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.

Authors:  Kannan Sridharan; Rachna Kataria; Drishti Tolani; Shital Bendkhale; Nithya J Gogtay; Urmila M Thatte
Journal:  Indian J Pharmacol       Date:  2016 Jul-Aug       Impact factor: 1.200

10.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.